Vitrase results presented at retinal society meeting

November 1, 2003

Irvine, CA -- Two phase III clinical trials of ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals) reveal a statistically significant reduction in vitreous hemorrhage density in patients with diabetes during each of 3 months following a single intravitreous injection of ovine hyaluronidase when compared with a single injection of saline solution.